Michael Yu, Innovent CEO
May 11, 2023 11:24 AM EDTUpdated 11:42 AM
R&D
China

In­novent show­cas­es topline PhII win for high-dose obe­si­ty drug in Chi­na

Amber Tong

In­novent is of­fer­ing up a fresh look at its obe­si­ty drug can­di­date, show­cas­ing an av­er­age 15.4% place­bo-ad­just­ed weight loss af­ter 24 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times